Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
FIA-586 by Novartis for Metabolic Dysfunction-Associated Steatohepatitis (MASH): Likelihood of Approval
FIA-586 is under clinical development by Novartis and currently in Phase I for Metabolic Dysfunction-Associated Steatohepatitis (MASH). According to GlobalData,...